Home > Insider Trading > Filing (0001179110-21-009952)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1159036	Halozyme Therapeutics Inc.	HALO	Biological Products, (No Disgnostic Substances) (2836)	880488686

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1528185	Helen Torley	C/O Halozyme Therapeutics, Inc. 11388 Sorrento Valley Road San Diego CA 92121	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-11-08	50,000	$14.66	587,160	No	4	M	Direct
Common Stock	Disposition	2021-11-08	37,775	$39.62	549,385	No	4	S	Direct
Common Stock	Disposition	2021-11-08	12,225	$40.42	537,160	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2021-11-08	50,000	$14.66	50,000	$14.66

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
150,000		2024-01-06	No	4	M	Direct

Footnotes

The option exercise and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 7, 2020, in accordance with Rule 10b5-1.
Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.25 to $40.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.